Folic Acid (FA)-tagged protein nanoemulsions were found to be preferentially internalized on B-cell lymphoma cell line (A20 cell line), which, for the first time, are reported to express folate receptor (FR)-alpha. Carbon monoxide releasing molecule-2 (CORM-2) was incorporated in the oil phase of the initial formulation. FAfunctionalized nanoemulsions loaded with CORM-2 exhibited a considerable antitumor effect and an increased survival of BALB/c mice bearing subcutaneous A20 lymphoma tumors. The developed nanoemulsions also demonstrated to be well tolerated by these immunocompetent mice. Thus, the results obtained in this study demonstrate that FAtagged protein nanoemulsions can be successfully used in cancer therapy, with the important ability to delivery drugs intracellularly. Res. 2007;41(1):120-9. 10. Foresti R, Bani-Hani M, Motterlini R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med. 2008;34(4):649-58. 11. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728-43.
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ACCEPTED MANUSCRIPT 4 Background Nanocarriers can modulate the pharmacokinetic and drug tissue distribution profile. 1, 2 Specific anticancer drug delivery is promoted including targeting ligands, 1, [3] [4] [5] such as folic acid (FA). 6 FA and FA conjugates bind with high affinity to folate receptor (FR)-alpha and -beta, and enter FR-expressing cells by receptor-mediated endocytosis. 7 FR-alpha expression is restricted to various normal epithelial cells, however it is overexpressed in several malignant cells and tissues. 8 FR-beta is a differentiation marker in normal hematopoiesis, being restricted to the myelomonocytic lineage and increasing during neutrophil maturation. FR-beta expression is also increased in activated monocytes/macrophages. 8 FA has emerged as a optimal targeting ligand with simple conjugation chemistry, non-immunogenicity and high affinity for the FR (K d = 10 -10 M) even after conjugation. 9 Nanocarriers functionalized with FA are widely studied for cancer targeting aplications.
Carbon monoxide (CO) has shown beneficial effects in mammals. 10-13 CO can induce growth arrest of human cancer cells, as well as murine AC29 mesothelioma cells. 14 The first compound described as able to carry and deliver controlled quantities of CO in cellular systems was the tricarbonyldichlororuthenium(II) dimer ([Ru(CO) 3 Cl 2 ] 2 ), known as CORM-2 (Carbon monoxide releasing molecule-2). 10, 11, [15] [16] [17] Ru has also been used independently in a variety of experimental anti-cancer drugs, with no acute or sub-acute toxicities reported. 15, 18 CORMs have been described as exhibiting a wide range of biological effects resulting in specific responses, which involve a restricted number of intracellular pathways and targets that encompass inflammation, apoptosis and cellular proliferation. 16 CORM-2, in particular, has been described to promote a beneficial therapeutic outcome in a number of mouse models of human disease. 15 However,
ACCEPTED MANUSCRIPT 5 CORM-2 has been shown to be highly unstable in plasma. Together with its observed anti-proliferative capacity, 19, 20 this support the advantage of targeted delivery of CORM-2 to cancer cells.
Here, we report the development of FA-tagged protein nanoemulsions loaded with CORM-2 for targeted drug delivery in a B-cell lymphoma model. Nanoemulsions were produced by high pressure homogenization of an aqueous phase (BSA solution containing a PEGylated surfactant and BSA-FA conjugate) with an organic phase (vegetable oil). Small, stable, PEGylated (described elsewhere 21 ) and FA-functionalized nanoemulsions were obtained and evaluated in terms of specific uptake using a lymphoma cell line (A20 cell line). The biological effect of the nanoemulsions loaded with CORM-2 was tested both in vitro and in vivo. The results obtained suggest the use of FA-tagged protein nanoemulsions for targeted drug delivery in cancer therapy.
Methods

Nanoemulsion preparation
Nanoemulsions were prepared using a high pressure homogenizer (APV-2000, Denmark 
Physicochemical characterization
The size distribution and zeta-potential values of the nanoemulsions were determined at Cell viability assay A20 cell viability was studied using the Promega CellTiter 96 ® AQueous Non-Radioactive Cell Proliferation (MTS) assay (Promega, USA). Cells were seeded in 24well tissue culture plates (Nunc, Denmark) at a density of 5×10 4 cells/well and coincubated with treatment conditions for determined incubation times. After coincubation, MTS was added and the cells were incubated for a further 4 hours at 37ºC.
After this period, the absorbance of the formazan product was read at 490 nm, using Spectra MAX 340PC microwell plate reader. Cell viability was expressed as a percentage relative to the negative control.
Uptake assay
Unbound BSA-FITC and BSA-FA were removed using Centricon tubes (Amicon Ultra-15, Millipore) and then the uptake of the nanoemulsions was evaluated. A20 cells were seeded at a density of 1×10 5 cells/well on coverslips pre-treated with Poly-L-lysine tumors to reach a volume greater than 1000 mm 3 . Mice body weight variations, during and after therapy, and survival curves for the different treatments applied were also determined.
Normal rodent feed contains a high concentration of FA (6 mg/kg feed), so mice were fed a FA-free diet (Harlan diet TD90261, Harlan Teklad) beginning 2 weeks before tumor implantation and maintained throughout the study in order to maintain serum FA concentrations closer to the range of normal human serum. 22, 23 Being these mice most commonly used for evaluating the performance of most anticancer agents and the high FA levels in mice sera could negatively affect the performance of FA-drug formulations used for cancer therapy, the majority of "FA-targeted" pharmacological studies published had involved the use of animals that were acclimated to some form of low/free FA chow. 23, 24 
Statistical analysis
Assumptions were met prior to data analysis. All data were tested for normality 
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Results
FA-tagged protein nanoemulsions and specific uptake by FR positive cells
We produced BSA nanoemulsions by high pressure homogenization of a BSA solution, containing a PEGylated surfactant, with vegetable oil ( Table 1 ). The characterization of these protein nanoemulsions is presented in Table 2 and is in line with what was previously described by our group, demonstrating that the particles are small, neutral surface (zeta-potential close to zero) and present high stability along time. 21 All these results establish that these PEGylated protein nanoemulsions have suitable characteristics required for systemic administration. Nanoemulsions containing imaging and targeting agents were prepared by introducing of BSA-FITC and BSA-FA conjugate in aqueous phase of initial formulation (Table 1) . To determine if FA at the nanoemulsion particle's surface promotes specific cell targeting and the endocytosis, the cellular uptake of nanoemulsions was evaluated in a B-cell lymphoma cell line (A20 cell line).
B-cell lymphoma is one of the most common hematologic malignancies and
targeted therapy based on monoclonal antibodies has become a treatment of choice in the clinic. However, a substantial number of patients experience a clinical relapse as a consequence of poor or no response to the treatments. 25 Several new targeting ligands have recently emerged for B-cell lymphoma treatment. 26 We confirmed by western blot that FR-alpha is expressed in A20 cells ( Figure 1A) , reported here for the first time. The
KB cell line was used as FR positive control and K562 cell line as FR negative control.
The evaluation of specific cellular uptake of nanoemulsions was performed by confocal laser scanning microscopy. It was observed that FA-functionalized nanoemulsions are more efficiently internalized by A20 cells (Figure 1B) . These results suggest that FA-functionalized nanoemulsions interact efficiently with FR-alpha at the
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cellular surface and promote FR-mediated endocytosis. By staining with phalloidin, which is a high-affinity F-actin probe, we showed that the nanoparticles were indeed internalized by the A20 cells. 3D reconstructions of images obtained by confocal microscopy allowed determining the number of nanoparticles internalized per cell ( Figure 1B) . We observed that, in average, approximately 7 fold more nanoparticles were internalized when FA is on the particle's surface.
FA-tagged protein nanoemulsions loaded with CORM-2 and specific drug delivery
We also evaluated the capacity of these BSA nanoemulsions for the selective delivery of drugs into FR expressing cells. We used CORM-2 as a model compound due to its described anti-proliferative capacity against cancer cells and its instability in plasma, which makes it an ideal candidate for encapsulation and targeted delivery.
Taking into account the production method described, the prepared nanoemulsions are especially efficient for the entrapment of hydrophobic drugs, such as CORM-2. The physicochemical characterization of the nanoemulsions containing FA at the surface and CORM-2 encapsulated was performed and we observed that the values of size, polydispersity index (PDI) and zeta-potential are very similar to the values presented by the nanoemulsions ( Table 2 ). The quantification of FA in these nanoemulsions was also performed using RIDASCREEN®FAST Folic acid test kit and the results showed a high concentration of FA at the surface of nanoemulsions ( Table 2 ).
In order to understand the mechanism responsible for the CORM-2 induced antiproliferative effect observed in A20 lymphoma cells (Figure 2A) , and taking into account the known link between CO and HO-1, we evaluated HO-1 expression and ROS levels in A20 exposed to different concentrations of CORM-2. We verified an increase of HO-1 protein expression in the presence of CORM-2, as reported in other
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT 13 pathologies (e.g. in kidney cells), 27 determined by Western blot analysis (Supporting information, Figure S1 ), however ROS production was not significantly altered (Supporting information, Figure S2 ). Figure 3A shows a considerable tumor growth inhibition when mice were treated with FA-functionalized nanoemulsions loaded with CORM-2, whilst empty FAfunctionalized nanoemulsions were shown to have no effect. The treatment with FAfunctionalized nanoemulsions containing CORM-2 substantially increased mice survival ( Figure 3B ). The in vivo study also demonstrated that the disclosed PEGylated BSA nanoemulsions were well tolerated in immunocompetent mice, with no detectable weight loss ( Figure 3C ).
FA
Discussion
We have developed FA-functionalized BSA nanoemulsions that demonstrated specific drug delivery into FR positive cancer cells. The expression of FR-alpha was confirmed in A20 B-cell lymphoma cells that were successfully targeted by FAfunctionalized BSA nanoemulsions.
CORMs, as CO, induce specific biological responses, through activation of a few intracellular pathways and targets, regulating inflammation, apoptosis and cellular proliferation. 16 CO has the ability to block cancer cell proliferation. 11 It appears that CO exerts its effect through different pathways in different cell lines and under different conditions. 11, 16 One of the central targets of CO seems to be the mithocondria and the overall bioenergetics of the cell. CO may promote mitochondrial biogenesis and drive mitochondria to increase ATP and ROS generation that in turn influence cellular behavior. Increasing ROS production would ultimately lead to induction of HO-1, which under certain circumstances may generate a positive feedback loop that contributes to the long-lasting beneficial effects of the HO1-CO pathway, perhaps
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involving other HO-1 products. 11 Our results indicate that in A20 cells, CORM-2 does in fact limit cell proliferation, possibly by involving HO-1 signaling but not affecting endogenous ROS levels.
The FA-tagged protein nanoemulsions loaded with CORM-2 led to considerable antitumor activity and the enhanced survival of mice bearing A20 lymphoma tumors.
One possibility to explain this notable antitumor activity of FA-tagged nanoemulsions loaded with CORM-2 is the reported CO's anti-cancer effect as a result of inducing anti-Warburg effect. 14 The Warburg effect provides substrates for cell growth and division and free energy (adenosine triphosphate, ATP) from enhanced glucose uptake and elevated glycolysis with a limited oxygen consumption rate. 14, 31 Exposure to CO uses this effect compelling the cancer cell to consume more oxygen that in turn drives metabolic demand, leading to growth inhibition, cellular exhaustion and death. 14 In the present study we chose a syngeneic model of B-cell lymphoma in the BALB/c mouse, which mimics human disease in an immunocompetent host. The subcutaneous model presents advantages such as visual confirmation that mice used in an experiment have tumors prior to therapy; and assessment to tumor response or growth over time. 30 Subcutaneous models may however be promiscuous of small particle penetration. 32 
Figure legends
Graphical Abstract
A novel therapeutic approach using folic acid (FA)-tagged protein nanoemulsions, as targeting carrier, and Carbon-Monoxide Releasing Molecule 2 (CORM-2) was described and discussed. FA-tagged protein nanoemulsions loaded with CORM-2, a hydrophobic anti-proliferative drug, induce a strong antitumor effect and increased the survival of mice bearing subcutaneous A20 lymphoma tumors.
